Effectiveness of 12 or 24 week LDV/SOF and 12 week LDV/SOF plus RBV in treatment-experienced patients with cirrhotic, genotype 1 Hepatitis C: Real-world experience from the TRIO Network

被引：0
|
作者：
Curry, Michael P. [1 ]
Bacon, Bruce [2 ]
Flamm, Steven L. [3 ]
Kowdley, Kris V. [4 ]
Dieterich, Douglas [5 ]
Milligan, Scott [6 ]
Tsai, Naoky C. S. C. [7 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] Northwestern Feinberg Sch Med, Chicago, IL USA
[4] Swedish Med Ctr, Liver Care Network, Seattle, WA USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Trio Hlth Analyt, Newton, MA USA
[7] Univ Hawaii, Queens Med Ctr, Honolulu, HI 96822 USA
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1108
引用
收藏
页码：755A / 755A
页数：1
相关论文
共 50 条
  • [1] EFFECTIVENESS OF 12 OR 24 WEEK LDV/SOF AND 12 WEEK LDV/SOF plus RBV IN TREATMENT-EXPERIENCED PATIENTS WITH CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK
    Curry, M.
    Bacon, B.
    Dieterich, D.
    Flamm, S.
    Guest, L.
    Kowdley, K.
    Lee, Y.
    Tsai, N.
    Younossi, Z.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A312 - A313
  • [2] EFFECTIVENESS OF 8 OR 12 WEEK LDV/SOF IN TREATMENT-NAIVE PATIENTS WITH NON-CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK
    Curry, M.
    Bacon, B.
    Dieterich, D.
    Flamm, S.
    Guest, L.
    Kowdley, K.
    Lee, Y.
    Tsai, N.
    Younossi, Z.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A313 - A313
  • [3] Effectiveness of 8 or 12 week LDV/SOF in treatment-naive patients with non-cirrhotic, genotype 1 Hepatitis C: Real-world experience from the TRIO Network
    Curry, Michael P.
    Bacon, Bruce
    Flamm, Steven L.
    Tsai, Naoky C. S. C.
    Dieterich, Douglas
    Milligan, Scott
    Kowdley, Kris V.
    [J]. HEPATOLOGY, 2015, 62 : 721A - 721A
  • [4] REALWORLD EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR (LDV/SOF) IN TREATMENT-EXPERIENCED CIRRHOTIC GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C: A COMPARATIVE ANALYSIS OF GILEAD SPONSORED TRIALS WITH 4 REAL-WORLD COHORTS
    Curry, M.
    Modi, A. A.
    Pungpapong, S.
    Leise, M.
    Aqel, B.
    Llewellyn, J.
    Williams, L. A.
    Natha, M.
    Brainard, D. M.
    Kreter, B.
    Kholi, A.
    Wyles, D.
    Lee, Y.
    Reddy, R.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S797 - S797
  • [5] Efficacy Evaluation of 24 Week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV Patients; Data From the TRIO Network
    Kowdley, Kris
    Bacon, Bruce
    Dieterich, Douglas T.
    Lawitz, Eric
    Milligan, Scott
    Tsai, Naoky
    Younossi, Zobair M.
    Flamm, Steven L.
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S1087 - S1087
  • [6] EFFICACY EVALUATION OF 24 WEEK SOF + RBV IN A HETEROGENEOUS, REAL-WORLD POPULATION OF GENOTYPE 3 HCV PATIENTS; DATA FROM THE TRIO NETWORK
    Kowdley, K.
    Bacon, B.
    Dieterich, D.
    Lawitz, E.
    Milligan, S.
    Tsai, N.
    Younossi, Z.
    Flamm, S.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S665 - S666
  • [7] Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/Sof) in Treatment-Experienced Cirrhotic Genotype 1 Patients With Chronic Hepatitis C (CHC): A Comparative Analysis of Gilead Sponsored Trials With 4 Real-World Cohorts (RWC)
    Flamm, Steven
    Modi, Apurva A.
    Pungpapong, Surakit
    Leise, Michael D.
    Aqel, Bashar
    Llewellyn, Joseph
    Williams, Laurie
    Natha, Macky
    Brainard, Diana
    Kreter, Bruce
    Kohli, Anita
    Wyles, David L.
    Lee, Yoori
    Reddy, K. R.
    Curry, Michael
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S1095 - S1095
  • [8] A Cost-Effectiveness Analysis of LDV/SOF+RBV for 12 Weeks vs. LDV/SOF 24 Weeks vs. SOF+SMV 24 Weeks in CHC Gt1 TE Cirrhotic Patients
    Ahmed, Aijaz
    Dieterich, Douglas T.
    Park, Haesuk
    Saab, Sammy
    Gordon, Stuart C.
    Younossi, Zobair M.
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S999 - S999
  • [9] Real-World Retreatment of Sofosbuvir/Ledipasvir (SOF/LDV) Failures In Hepatitis C Virus Genotype 1 infection
    Pearlman, Brian
    Hinds, Andrew
    Perrys, Michael
    [J]. HEPATOLOGY, 2016, 64 : 478A - 478A
  • [10] Effectiveness of 8 vs. 12 week ledipasvir-sofosbuvir (LDV/SOF) in black, treatment naive patients with non-cirrhotic, genotype 1 HCV and baseline viral load
    Curry, M.
    Bacon, B.
    Flamm, S.
    Landen, A.
    Milligan, S.
    Tsai, N.
    Younossi, Z.
    Afdhal, N.
    [J]. JOURNAL OF HEPATOLOGY, 2018, 68 : S271 - S272
12345